81 FR 22023 - Schedules of Controlled Substances: Placement of AH-7921 Into Schedule I
DEPARTMENT OF JUSTICE
Drug Enforcement Administration Federal Register Volume 81, Issue 72 (April 14, 2016)
Drug Enforcement Administration
Federal Register Volume 81, Issue 72 (April 14, 2016)
| Page Range | 22023-22025 | |
| FR Document | 2016-08566 |
[Federal Register Volume 81, Number 72 (Thursday, April 14, 2016)] [Rules and Regulations] [Pages 22023-22025] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-08566] ======================================================================== Rules and Regulations Federal Register ________________________________________________________________________ This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510. The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week. ======================================================================== Federal Register / Vol. 81, No. 72 / Thursday, April 14, 2016 / Rules and Regulations [[Page 22023]] DEPARTMENT OF JUSTICE Drug Enforcement Administration 21 CFR Part 1308 [Docket No. DEA-432] Schedules of Controlled Substances: Placement of AH-7921 Into Schedule I AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Final order. ----------------------------------------------------------------------- SUMMARY: With the issuance of this final order, the Administrator of the Drug Enforcement Administration places the substance AH-7921 (Systematic IUPAC Name: 3,4-dichloro-N- [(1dimethylamino)cyclohexylmethyl]benzamide), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, into schedule I of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act and is required in order for the United States to discharge its obligations under the Single Convention on Narcotic Drugs, 1961. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research or conduct instructional activities with, or possess), or propose to handle, AH-7921. DATES: Effective May 16, 2016. FOR FURTHER INFORMATION CONTACT: Barbara J. Boockholdt, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598-6812. SUPPLEMENTARY INFORMATION: Legal Authority The Drug Enforcement Administration (DEA) implements and enforces titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. Titles II and III are referred to as the ``Controlled Substances Act'' and the ``Controlled Substances Import and Export Act,'' respectively, and are collectively referred to as the ``Controlled Substances Act'' or the ``CSA'' for the purpose of this action. 21 U.S.C. 801-971. The DEA publishes the implementing regulations for these statutes in title 21 of the Code of Federal Regulations (CFR), chapter II. The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while providing for the legitimate medical, scientific, research, and industrial needs of the United States. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety. Under the CSA, controlled substances are classified into one of five schedules based upon their potential for abuse, their currently accepted medical use in treatment in the United States, and the degree of dependence the substance may cause. 21 U.S.C. 812. The initial schedules of controlled substances established by Congress are found at 21 U.S.C. 812(c), and the current list of scheduled substances is published at 21 CFR part 1308. Section 201(d)(1) of the CSA (21 U.S.C. 811(d)(1)) states that, if control of a substance is required ``by United States obligations under international treaties, conventions, or protocols in effect on October 27, 1970, the Attorney General shall issue an order controlling such drug under the schedule he deems most appropriate to carry out such obligations, without regard to the findings and procedures required by section 201(a) and (b) (21 U.S.C. 811(a) and (b)) and section 202(b) (21 U.S.C. 812(b)) of the Act.'' 21 U.S.C. 811(d)(1), 21 CFR 1308.46. If a substance is added to one of the schedules of the Single Convention on Narcotic Drugs, 1961, then, in accordance with article 3, paragraph 7 of the Convention, as a signatory Member State, the United States is obligated to control that substance under its national drug control legislation, the CSA. The Attorney General has delegated scheduling authority under 21 U.S.C. 811 to the Administrator of the DEA. 28 CFR 0.100. Background On May 8, 2015, the Secretary-General of the United Nations advised the Secretary of State of the United States, that during the 58th session of the Commission on Narcotic Drugs, AH-7921 was added to schedule I of the Single Convention on Narcotic Drugs, 1961. This letter was prompted by a decision at the 58th session of the Commission on Narcotic Drugs in March 2015 to schedule AH-7921 under schedule I of the Single Convention on Narcotic Drugs. As a signatory Member State to the Single Convention on Narcotic Drugs, the United States is obligated to control AH-7921 under its national drug control legislation, the CSA, in the schedule deemed most appropriate to carry out its international obligations. 21 U.S.C. 811(d)(1). AH-7921 AH-7921 is an N-substituted cyclohexylmethyl benzamide developed in 1962 by Allen and Hanbury's, Ltd., a pharmaceutical company in the United Kingdom. AH-7921 is a [micro]-opioid receptor agonist with analgesic activity similar to that of morphine. The DEA is not aware of any commercial or medical uses for this substance. In animals, withdrawal symptoms are observed following repeated administration of AH-7921. Currently, clinical studies evaluating the safety and pharmacological effects of AH-7921 in humans have not been reported in the scientific literature. Usage of AH-7921 for eliciting euphoria and relaxation has been documented. There have been several reports of overdoses and deaths from AH-7921 reported worldwide including at least one published case report of a death resulting from AH-7921 in the United States. Given the increasing abuse of opioid prescription drugs (e.g., oxycodone, hydrocodone and fentanyl) and increased use of heroin in the United States, there are legitimate concerns about an increased potential of abuse of AH-7921. DEA is not aware of any claims or any medical or scientific literature suggesting that AH-7921 has a currently accepted medical use in treatment in the United States. Accordingly, DEA has not requested that HHS conduct a scientific and medical evaluation of the substance's medical utility. [[Page 22024]] Furthermore, DEA is not required under 21 U.S.C. 811(d)(1) to make any findings required by 21 U.S.C. 811(a) or 812(b), and is not required to follow the procedures prescribed by 21 U.S.C. 811(a) and (b). Therefore, consistent with the framework of 21 U.S.C. 811(d), DEA concludes that AH-7921 has no currently accepted medical use in treatment in the United States and is most appropriately placed in schedule I of the CSA. Conclusion In order to meet the obligations of the Single Convention on Narcotic Drugs, 1961 and because AH-7921 has no currently accepted medical use in treatment in the United States, the Administrator of the Drug Enforcement Administration has determined that this substance should be placed in schedule I of the Controlled Substances Act. Requirements for Handling Upon the effective date of this final order, AH-7921 is subject to the CSA's schedule I regulatory controls and administrative, civil, and criminal sanctions applicable to the manufacture, distribution, importation, exportation, engagement in research, and conduct of instructional activities with, and possession of schedule I controlled substances including the following: 1. Registration. Any person who handles (manufactures, distributes, imports, exports, engages in research or conducts instructional activities with, or possesses), or who desires to handle, AH-7921 must be registered with the DEA to conduct such activities pursuant to 21 U.S.C. 822, 823, 957, and 958 and in accordance with 21 CFR parts 1301 and 1312, as of May 16, 2016. Any person who currently handles AH-7921, and is not registered with the DEA, must submit an application for registration and may not continue to handle AH-7921 as of May 16, 2016, unless the DEA has approved that application for registration pursuant to 21 U.S.C. 822, 823, 957, 958, and in accordance with 21 CFR parts 1301 and 1312. 2. Disposal of stocks. Any person who does not desire or is not able to obtain a schedule I registration must surrender all quantities of currently held AH-7921, or may transfer all quantities of currently held AH-7921 to a person registered with the DEA on or before May 16, 2016 in accordance with all applicable federal, state, local, and tribal laws. As of May 16, 2016, controlled substances must be disposed of in accordance with 21 CFR part 1317, in additional to all other applicable federal, state, local, and tribal laws. 3. Security. AH-7921 is subject to schedule I security requirements and must be handled and stored pursuant to 21 U.S.C. 821, 823, 871(b), and in accordance with 21 CFR 1301.71-1301.93, as of May 16, 2016. 4. Labeling and packaging. All labels, labeling, and packaging for commercial containers of AH-7921 must be in compliance with 21 U.S.C. 825, 958(e), and be in accordance with 21 CFR part 1302 as of May 16, 2016. 5. Quota. A quota assigned pursuant to 21 U.S.C. 826 and in accordance with 21 CFR part 1303 is required in order to manufacture AH-7921 as of May 16, 2016. 6. Inventory. Every DEA registrant who possesses any quantity of AH-7921 on the effective date of this order must take an inventory of all stocks of this substance on hand as of May 16, 2016, pursuant to 21 U.S.C. 827 and 958, and in accordance with Sec. Sec. 1304.03, 1304.04, and 1304.11. Any person who becomes registered with the DEA after May 16, 2016 must take an initial inventory of all stocks of controlled substances (including AH-7921) on hand on the date the registrant first engages in the handling of controlled substances, pursuant to 21 U.S.C. 827 and 958 and in accordance with 21 CFR 1304.03, 1304.04, and 1304.11. After the initial inventory, every DEA registrant must take an inventory of all controlled substances (including AH-7921) on hand on a biennial basis, pursuant to 21 U.S.C. 827 and 958, and in accordance with Sec. Sec. 1304.03, 1304.04, and 1304.11. 7. Records and Reports. Every DEA registrant would be required to maintain records and submit reports with respect to AH-7921 pursuant to 21 U.S.C. 827 and 958, and in accordance with 21 CFR parts 1304 and 1312. 8. Order Forms. All DEA registrants who distribute AH-7921 must comply with order form requirements pursuant to 21 U.S.C. 828 and in accordance with 21 CFR part 1305 as of May 16, 2016. 9. Importation and Exportation. All importation and exportation of AH-7921 must be in compliance with 21 U.S.C. 952, 953, 957, 958, and in accordance with 21 CFR part 1312 as of May 16, 2016. 10. Liability. Any activity involving AH-7921 not authorized by, or in violation of the CSA, occurring as of May 16, 2016, is unlawful, and may subject the person to administrative, civil, and/or criminal sanctions. Regulatory Analyses Administrative Procedure Act The CSA provides for an expedited scheduling action where control is required by the United States obligations under international treaties, conventions, or protocols. 21 U.S.C. 811(d)(1). If control is required pursuant to such international treaty, convention, or protocol, the Attorney General must issue an order controlling such drug under the schedule he deems most appropriate to carry out such obligations, without regard to the findings or procedures otherwise required for scheduling actions. Id. To the extent that 21 U.S.C. 811(d)(1) directs that if control is required by the United States obligations under international treaties, conventions, or protocols in effect on October 27, 1970, scheduling actions shall be issued by order (as compared to scheduling pursuant to 21 U.S.C. 811(a) by rule), the DEA believes that the notice and comment requirements of section 553 of the Administrative Procedure Act (APA), 5 U.S.C. 553, do not apply to this scheduling action. In the alternative, even if this action does constitute ``rule making'' under 5 U.S.C. 551(5), this action is exempt from the notice and comment requirements of 5 U.S.C. 553 pursuant to 21 U.S.C. 553(a)(1) as an action involving a foreign affairs function of the United States given that this action is being done in accordance with 21 U.S.C. 811(d)(1)'s requirement that such action be taken to comply with the United States obligations under the specified international agreements. Executive Order 12866 This action is not a significant regulatory action as defined by Executive Order 12866 (Regulatory Planning and Review), section 3(f), and, accordingly, this action has not been reviewed by the Office of Management and Budget (OMB). Executive Order 13132 This action does not have federalism implications warranting the application of Executive Order 13132. This action will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, in accordance with Executive Order 13132 (Federalism) it is determined that this action does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment. [[Page 22025]] Executive Order 13175 This action does not have tribal implications warranting the application of Executive Order 13175. The action does not have substantial direct effects on one or more Indian tribes, on the relationship between the Federal government and Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes. Regulatory Flexibility Act The Regulatory Flexibility Act (RFA) (5 U.S.C. 601-612) applies to rules that are subject to notice and comment under section 553(b) of the APA or any other law. As explained above, the CSA exempts this final order from notice and comment. Consequently, the RFA does not apply to this action. Paperwork Reduction Act of 1995 This action does not impose a new collection of information requirement under the Paperwork Reduction Act of 1995. 44 U.S.C. 3501- 3521. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Congressional Review Act This action is not a major rule as defined by section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996 (Congressional Review Act). However, the DEA has submitted a copy of this final order to both Houses of Congress and to the Comptroller General. List of Subjects in 21 CFR Part 1308 Administrative practice and procedure, Drug traffic control, Narcotics, Prescription drugs. For the reasons set out above, the DEA amends 21 CFR part 1308 as follows: PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES 0 1. The authority citation for part 1308 continues to read as follows: Authority: 21 U.S.C. 811, 812, 871(b), unless otherwise noted. 0 2. Amend Sec. 1308.11 by redesignating paragraphs (b)(3) through (55) as (b)(4) through (56) and adding a new (b)(3)to read as follows: Sec. 1308.11 Schedule I. * * * * * (b) * * * (3) AH-7921 (3,4-dichloro-N-[(1-dimethylamino) 9551 cyclohexylmethyl]benzamide.................................... * * * * * Dated: April 8, 2016 Chuck Rosenberg, Acting Administrator. [FR Doc. 2016-08566 Filed 4-13-16; 8:45 am] BILLING CODE 4410-09-P
![22023
Rules and Regulations Federal Register
Vol. 81, No. 72
Thursday, April 14, 2016
This section of the FEDERAL REGISTER Comprehensive Drug Abuse Prevention 811 to the Administrator of the DEA. 28
contains regulatory documents having general and Control Act of 1970, as amended. CFR 0.100.
applicability and legal effect, most of which Titles II and III are referred to as the
are keyed to and codified in the Code of Background
‘‘Controlled Substances Act’’ and the
Federal Regulations, which is published under On May 8, 2015, the Secretary-
‘‘Controlled Substances Import and
50 titles pursuant to 44 U.S.C. 1510. General of the United Nations advised
Export Act,’’ respectively, and are
The Code of Federal Regulations is sold by collectively referred to as the the Secretary of State of the United
the Superintendent of Documents. Prices of ‘‘Controlled Substances Act’’ or the States, that during the 58th session of
new books are listed in the first FEDERAL ‘‘CSA’’ for the purpose of this action. 21 the Commission on Narcotic Drugs, AH-
REGISTER issue of each week. U.S.C. 801–971. The DEA publishes the 7921 was added to schedule I of the
implementing regulations for these Single Convention on Narcotic Drugs,
statutes in title 21 of the Code of Federal 1961. This letter was prompted by a
DEPARTMENT OF JUSTICE Regulations (CFR), chapter II. The CSA decision at the 58th session of the
and its implementing regulations are Commission on Narcotic Drugs in
Drug Enforcement Administration March 2015 to schedule AH-7921 under
designed to prevent, detect, and
schedule I of the Single Convention on
eliminate the diversion of controlled
21 CFR Part 1308 Narcotic Drugs. As a signatory Member
substances and listed chemicals into the
State to the Single Convention on
[Docket No. DEA–432] illicit market while providing for the
Narcotic Drugs, the United States is
legitimate medical, scientific, research,
Schedules of Controlled Substances: obligated to control AH-7921 under its
and industrial needs of the United national drug control legislation, the
Placement of AH-7921 Into Schedule I States. Controlled substances have the CSA, in the schedule deemed most
AGENCY: Drug Enforcement potential for abuse and dependence and appropriate to carry out its international
Administration, Department of Justice. are controlled to protect the public obligations. 21 U.S.C. 811(d)(1).
health and safety.
ACTION: Final order. AH-7921
Under the CSA, controlled substances
SUMMARY: With the issuance of this final are classified into one of five schedules AH-7921 is an N-substituted
order, the Administrator of the Drug based upon their potential for abuse, cyclohexylmethyl benzamide developed
Enforcement Administration places the their currently accepted medical use in in 1962 by Allen and Hanbury’s, Ltd., a
substance AH-7921 (Systematic IUPAC treatment in the United States, and the pharmaceutical company in the United
Name: 3,4-dichloro-N-[(1dimethy degree of dependence the substance Kingdom. AH-7921 is a m-opioid
lamino)cyclohexylmethyl]benzamide), may cause. 21 U.S.C. 812. The initial receptor agonist with analgesic activity
including its isomers, esters, ethers, schedules of controlled substances similar to that of morphine. The DEA is
salts, and salts of isomers, esters and established by Congress are found at 21 not aware of any commercial or medical
ethers, into schedule I of the Controlled U.S.C. 812(c), and the current list of uses for this substance. In animals,
Substances Act. This scheduling action scheduled substances is published at 21 withdrawal symptoms are observed
is pursuant to the Controlled Substances CFR part 1308. following repeated administration of
Act and is required in order for the AH-7921. Currently, clinical studies
Section 201(d)(1) of the CSA (21 evaluating the safety and
United States to discharge its
U.S.C. 811(d)(1)) states that, if control of pharmacological effects of AH-7921 in
obligations under the Single Convention
a substance is required ‘‘by United humans have not been reported in the
on Narcotic Drugs, 1961. This action
States obligations under international scientific literature. Usage of AH-7921
imposes the regulatory controls and
treaties, conventions, or protocols in for eliciting euphoria and relaxation has
administrative, civil, and criminal
effect on October 27, 1970, the Attorney been documented. There have been
sanctions applicable to schedule I
General shall issue an order controlling several reports of overdoses and deaths
controlled substances on persons who
such drug under the schedule he deems from AH-7921 reported worldwide
handle (manufacture, distribute, import,
most appropriate to carry out such including at least one published case
export, engage in research or conduct
obligations, without regard to the report of a death resulting from AH-
instructional activities with, or possess),
findings and procedures required by 7921 in the United States. Given the
or propose to handle, AH-7921.
section 201(a) and (b) (21 U.S.C. 811(a) increasing abuse of opioid prescription
DATES: Effective May 16, 2016. and (b)) and section 202(b) (21 U.S.C. drugs (e.g., oxycodone, hydrocodone
FOR FURTHER INFORMATION CONTACT: 812(b)) of the Act.’’ 21 U.S.C. 811(d)(1), and fentanyl) and increased use of
Barbara J. Boockholdt, Office of 21 CFR 1308.46. If a substance is added heroin in the United States, there are
Diversion Control, Drug Enforcement to one of the schedules of the Single legitimate concerns about an increased
Administration; Mailing Address: 8701 Convention on Narcotic Drugs, 1961, potential of abuse of AH-7921.
asabaliauskas on DSK3SPTVN1PROD with RULES
Morrissette Drive, Springfield, Virginia then, in accordance with article 3, DEA is not aware of any claims or any
22152; Telephone: (202) 598–6812. paragraph 7 of the Convention, as a medical or scientific literature
SUPPLEMENTARY INFORMATION: signatory Member State, the United suggesting that AH-7921 has a currently
States is obligated to control that accepted medical use in treatment in the
Legal Authority substance under its national drug United States. Accordingly, DEA has not
The Drug Enforcement control legislation, the CSA. The requested that HHS conduct a scientific
Administration (DEA) implements and Attorney General has delegated and medical evaluation of the
enforces titles II and III of the scheduling authority under 21 U.S.C. substance’s medical utility.
VerDate Sep<11>2014 17:42 Apr 13, 2016 Jkt 238001 PO 00000 Frm 00001 Fmt 4700 Sfmt 4700 E:\FR\FM\14APR1.SGM 14APR1](https://thefederalregister.org/doc/81_FR_22095/page/1.svg)
![Federal Register / Vol. 81, No. 72 / Thursday, April 14, 2016 / Rules and Regulations 22025
Executive Order 13175 * * * * * Need for Correction
This action does not have tribal Dated: April 8, 2016 As published, the final preamble
implications warranting the application Chuck Rosenberg, contains an error in a table identifying
of Executive Order 13175. The action Acting Administrator. areas subject to the findings of failure to
does not have substantial direct effects [FR Doc. 2016–08566 Filed 4–13–16; 8:45 am] submit related to the Indiana,
on one or more Indian tribes, on the BILLING CODE 4410–09–P
Pennsylvania nonattainment area. The
relationship between the Federal Indiana, Pennsylvania nonattainment
government and Indian tribes, or on the area consists of the entirety of Indiana
distribution of power and County and part of Armstrong County.
responsibilities between the Federal ENVIRONMENTAL PROTECTION See 78 FR 47191, August 5, 2013
government and Indian tribes. AGENCY codified at 40 CFR part 81, subpart C.
Regulatory Flexibility Act The preamble table mistakenly lists
40 CFR Part 52 Indiana County as a ‘‘partial’’ county
The Regulatory Flexibility Act (RFA) that is part of the Indiana, Pennsylvania
(5 U.S.C. 601–612) applies to rules that [EPA–HQ–OAR–2016–0098; FRL–9944–88– nonattainment area subject to a finding
are subject to notice and comment OAR] of failure to submit, when the full
under section 553(b) of the APA or any county should have been listed as
other law. As explained above, the CSA Findings of Failure To Submit State subject to the finding. Additional notice
exempts this final order from notice and Implementation Plans Required for and comment for this minor technical
comment. Consequently, the RFA does Attainment of the 2010 1-Hour Primary correction is unnecessary under 5 U.S.C.
not apply to this action. Sulfur Dioxide National Ambient Air 553(b)(3)(B), and the EPA finds that
Paperwork Reduction Act of 1995 Quality Standard (NAAQS); Correction good cause exists for this minor
AGENCY: Environmental Protection technical correction to become effective
This action does not impose a new
Agency (EPA). at the same time as the final rule.
collection of information requirement
Accordingly, this correction is
under the Paperwork Reduction Act of ACTION: Final rule; correction.
incorporated into the final rule and also
1995. 44 U.S.C. 3501–3521. An agency
SUMMARY: The Environmental Protection becomes effective on April 18, 2016.
may not conduct or sponsor, and a
person is not required to respond to, a Agency (EPA) is correcting a final rule Correction of Publication
collection of information unless it that appeared in the Federal Register on
March 18, 2016 (81 FR 14736). The In FR Doc 2016–06063 appearing on
displays a currently valid OMB control page 14736 in the Federal Register of
number. document included a listing of areas for
which states had not submitted State Friday, March 18, 2016, the following
Congressional Review Act Implementation Plans (SIPs) addressing correction is made:
On page 14737, table entitled
This action is not a major rule as nonattainment area SIP requirements for
‘‘STATES AND SO2
defined by section 804 of the Small the 2010 1-hour primary sulfur dioxide
NONATTAINMENT AREAS AFFECTED
Business Regulatory Enforcement (SO2) NAAQS. This action corrects that
BY THESE FINDINGS OF FAILURE TO
Fairness Act of 1996 (Congressional listing to clarify that the Indiana,
SUBMIT,’’ remove from the end of the
Review Act). However, the DEA has Pennsylvania nonattainment area for the
fourth entry, under the column titled
submitted a copy of this final order to 2010 SO2 NAAQS consists of the
‘‘Nonattainment area’’ the text ‘‘(p)’’.
both Houses of Congress and to the entirety of Indiana County and part of
Comptroller General. Armstrong County. Dated: April 4, 2016.
DATES: The effective date of this Janet G. McCabe,
List of Subjects in 21 CFR Part 1308
document is April 18, 2016. Acting Assistant Administrator.
Administrative practice and [FR Doc. 2016–08509 Filed 4–13–16; 8:45 am]
FOR FURTHER INFORMATION CONTACT: For
procedure, Drug traffic control,
Narcotics, Prescription drugs. questions regarding this correction, BILLING CODE 6560–50–P
contact Dr. Larry Wallace, U.S.
For the reasons set out above, the DEA
Environmental Protection Agency,
amends 21 CFR part 1308 as follows: ENVIRONMENTAL PROTECTION
Office of Air Quality Planning and
Standards, Mail Code C539–01, AGENCY
PART 1308—SCHEDULES OF
CONTROLLED SUBSTANCES Research Triangle Park, NC 27711,
40 CFR Part 52
phone number (919) 541-0906 or by
■ 1. The authority citation for part 1308 email at wallace.larry@epa.gov. [EPA–R09–OAR–2015–0204; FRL–9944–16–
continues to read as follows: SUPPLEMENTARY INFORMATION:
Region 9]
Authority: 21 U.S.C. 811, 812, 871(b), Partial Approval and Partial
Background
unless otherwise noted.
Disapproval of Air Quality State
The EPA issued the final rule, in FR
■ 2. Amend § 1308.11 by redesignating Implementation Plans; California;
Doc 2016–06063 on March 18, 2016 (81
paragraphs (b)(3) through (55) as (b)(4) South Coast; Moderate Area Plan for
FR 14736). That final rule establishes
through (56) and adding a new (b)(3)to the 2006 PM2.5 NAAQS
certain Clean Air Act deadlines for the
read as follows:
asabaliauskas on DSK3SPTVN1PROD with RULES
EPA to impose sanctions if a state does AGENCY: U.S. Environmental Protection
§ 1308.11 Schedule I. not submit a SIP addressing Agency (EPA).
* * * * * nonattainment area SIP requirements to ACTION: Final rule.
(b) * * * bring the affected areas into attainment
of the 2010 1-hour primary SO2 NAAQS SUMMARY: The Environmental Protection
(3) AH-7921 (3,4-dichloro-N-[(1- and for the EPA to promulgate a Federal Agency (EPA) is approving in part and
dimethylamino) Implementation Plan to address any disapproving in part State
cyclohexylmethyl]benzamide ......... 9551 outstanding SIP requirements. implementation plan (SIP) revisions
VerDate Sep<11>2014 14:21 Apr 13, 2016 Jkt 238001 PO 00000 Frm 00003 Fmt 4700 Sfmt 4700 E:\FR\FM\14APR1.SGM 14APR1](https://thefederalregister.org/doc/81_FR_22095/page/3.svg)
Document Created: 2018-02-07 13:47:58
Document Modified: 2018-02-07 13:47:58
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Rules and Regulations | |
| Action | Final order. | |
| Dates | Effective May 16, 2016. | |
| Contact | Barbara J. Boockholdt, Office of | |
| FR Citation | 81 FR 22023 | |
| CFR Associated | Administrative Practice and Procedure; Drug Traffic Control; Narcotics and Prescription Drugs |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR